Skip to main content

F-star Therapeutics, Inc.

FSTXDelisted Mar 9, 2023
Industry
Pharmaceutical Preparations
SEC CIK
0001566373

F-star Therapeutics, Inc. was delisted on Mar 9, 2023; its insiders filed their last Form 4 on Mar 9, 2023; 59 institutions reported holding it in 13F filings for Q4 2022, worth $57.8M in total; Fairfax Financial was the only superinvestor holding it.

Currency
USD
Source
SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
Updated
Oct 8, 2026, 1:32 PM ET

Revenue flow, Q3 FY2022

Where the revenue went in Q3 FY2022, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.

Net loss for Q3 FY2022: $18.4M (1636.2% of revenue).

Income statement

Each column is one quarter, newest first.

Income statement of F-star Therapeutics, Inc., quarterly
Line itemQ3 FY2022Q2 FY2022Q1 FY2022Q4 FY2021†Q3 FY2021Q2 FY2021Q1 FY2021Q4 FY2020†
Period endSep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020
Filing10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K
Reported–Aug 11, 2022May 10, 2022Mar 14, 2022Nov 10, 2021Aug 12, 2021May 17, 2021Mar 29, 2021
Revenue$1.13M$0$2.55M$17.5M†$751.0K$0$2.92M–
Research and development$9.67M$8.72M$8.04M$8.21M†$5.11M$8.44M$7.27M$3.10M†
Selling, general and administrative$5.16M$7.46M$5.70M$4.96M†$5.24M$6.50M$6.43M$11.6M†
Operating income-$13.7M-$16.2M-$11.2M$4.32M†-$9.60M-$14.9M-$10.8M-$3.49M†
Interest expense$378.0K$334.0K$308.0K$775.0K†––––
Income tax$0$0–-$562.0K†$0$82.0K$108.0K-$1.00K†
Net income-$18.4M-$19.0M-$12.1M$4.74M†-$10.8M-$15.6M-$9.87M-$5.54M†
EPS, basic$-0.84$-0.88––––––
EPS, diluted$-0.84$-0.88––––––
Weighted shares, basic21.9M21.6M––––––
Weighted shares, diluted21.9M21.6M––––––
Margins and growth
Operating margin-1218.3%–-438.6%24.7%-1278.4%–-369.5%–
Net margin-1636.2%–-473.8%27.1%-1436.9%–-338.3%–
Revenue growth, year over year+49.8%–−12.5%–––––

Balance sheet

Each column is one quarter, newest first.

Balance sheet of F-star Therapeutics, Inc., quarterly
Line itemQ3 FY2022Q2 FY2022Q1 FY2022Q4 FY2021†Q3 FY2021Q2 FY2021Q1 FY2021Q4 FY2020†
Period endSep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020
Filing10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K
Reported–Aug 11, 2022May 10, 2022Mar 14, 2022Nov 10, 2021Aug 12, 2021May 17, 2021Mar 29, 2021
Cash and equivalents$35.6M$53.0M$68.8M$78.5M$71.0M$81.6M$3.68M$18.5M
Accounts receivable––––––$2.80M–
Total current assets$49.6M$64.9M$77.3M$84.7M$76.2M$85.3M$13.8M$26.1M
Property, plant and equipment$879.0K$813.0K$743.0K$887.0K$1.01M$1.16M$1.06M$789.0K
Goodwill$14.1M$14.5M$14.8M$14.9M$14.9M$15.0M$15.0M$14.9M
Intangible assets$16.2M$17.3M$18.4M$18.8M$18.8M$19.2M$19.2M$19.0M
Total assets$83.7M$100.6M$114.7M$123.0M$114.8M$125.0M$53.4M$63.6M
Accounts payable$2.50M$4.05M$4.31M$3.08M$1.57M$2.43M$4.08M$4.60M
Short-term debt$1.31M$353.0K–––––$0
Total current liabilities$14.7M$15.3M$12.7M$12.1M$8.84M$9.95M$14.3M$17.0M
Long-term debt$8.53M$9.40M$9.68M$9.61M$9.54M$9.47M––
Total liabilities$26.8M$29.0M$26.5M$26.2M$24.7M$26.0M$18.6M$20.6M
Shareholders' equity$56.9M$71.6M$88.2M$96.9M$90.1M$99.0M$34.8M$43.0M

Cash flow statement

Each column is one quarter, newest first. Free cash flow is operating cash flow minus capital expenditures.

Cash flow statement of F-star Therapeutics, Inc., quarterly
Line itemQ3 FY2022†Q2 FY2022†Q1 FY2022Q4 FY2021†Q3 FY2021†Q2 FY2021†Q1 FY2021Q4 FY2020†
Period endSep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020
Filing10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K
Reported–Aug 11, 2022May 10, 2022Mar 14, 2022Nov 10, 2021Aug 12, 2021May 17, 2021Mar 29, 2021
Operating cash flow-$16.5M†-$16.5M†-$11.6M$6.78M†-$10.7M†-$8.96M†-$14.4M-$496.0K†
Capital expenditures$47.0K†––$0†$0†$391.0K†$267.0K–
Free cash flow-$16.6M––$6.78M-$10.7M-$9.35M-$14.6M–
Stock-based compensation$1.45M†$1.42M†$1.45M$1.34M†$1.51M†$1.86M†$2.18M$1.75M†
Investing cash flow$1.00K†––$0†$0†-$391.0K†-$252.0K-$2.18M†
Financing cash flow$5.00K†$303.0K†$1.88M$1.05M†$2.00K†$87.0M†$0$35.3M†
Net change in cash-$16.5M†-$16.6M†-$9.74M$7.83M†-$10.7M†$77.7M†-$14.6M$32.6M†
Ratio
Stock-based compensation, % of revenue128.5%–57.0%7.7%201.7%–74.7%–

Shares outstanding

Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.

Shares outstanding for F-star Therapeutics, Inc. by cover date
Cover dateShares outstandingChange in a yearFiling
Sep 30, 202222.0M+6.6%SEC
Jun 30, 202221.6M+4.7%SEC
Mar 31, 202221.5M+136.2%SEC
Mar 1, 202221.1M+131.5%SEC
Nov 8, 202120.6M+19.4%SEC
Aug 7, 202120.6M+19.5%SEC
May 12, 202119.4M+13.3%SEC
Mar 24, 20219.10M−46.8%SEC

Notes and known gaps

How these numbers are put together, and what they can't tell you.

  • Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
  • Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
  • Values marked † are derived: Q4 is the full year minus the first three quarters, single-quarter cash flows are year-to-date figures minus the previous year-to-date figures, and the Q4 balance sheet is the year-end balance sheet.

Known gaps

  • Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
  • EPS and share counts are as reported at the time, not adjusted for later stock splits.
  • For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
  • For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
  • Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
  • Depreciation and amortization is missing for some companies that report it under their own XBRL tags.